AbbVie (ABBV) EBITDA (2012 - 2026)
AbbVie (ABBV) posted quarterly EBITDA of $4.0 billion for Q1 2026, up 6.88% year-over-year from $3.7 billion in Q1 2025, and down 12.19% quarter-over-quarter from $4.5 billion in Q4 2025.
AbbVie (ABBV) EBITDA (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported EBITDA for 15 consecutive years, with $4.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 6.88% year-over-year to $4.0 billion; the TTM figure through Mar 2026 stood at $15.3 billion (up 52.22% YoY), while the FY2025 annual figure was $15.1 billion, up 64.99% from the prior year.
- EBITDA retreated to $4.0 billion in Q1 2026 per ABBV's latest filing, from $4.5 billion in the prior quarter.
- Across five years, EBITDA topped out at $5.5 billion in Q4 2022 and bottomed at -$1.5 billion in Q4 2024.
- Historically, EBITDA has averaged $3.5 billion across 5 years, with a median of $3.8 billion in 2024.
- Annual changes were most pronounced in 2024 — EBITDA sank 146.64% — and 2025, when it soared 404.97%.
- AbbVie's EBITDA stood at $5.5 billion in 2022, then slumped by 41.93% to $3.2 billion in 2023, then tumbled by 146.64% to -$1.5 billion in 2024, then jumped by 404.97% to $4.5 billion in 2025, then retreated by 12.19% to $4.0 billion in 2026.
- Business Quant data shows ABBV's EBITDA at $4.0 billion in Q1 2026, $4.5 billion in Q4 2025, and $1.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 16.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.43 Bn |
| Mar 31, 2026 | 3.99 Bn |
| Dec 31, 2025 | 4.54 Bn |
| Sep 30, 2025 | 1.90 Bn |
| Jun 30, 2025 | 4.89 Bn |
| Mar 31, 2025 | 3.73 Bn |
| Dec 31, 2024 | -1.49 Bn |
| Sep 30, 2024 | 3.83 Bn |
| Jun 30, 2024 | 4.00 Bn |
| Mar 31, 2024 | 2.80 Bn |
| Dec 31, 2023 | 3.20 Bn |
| Sep 30, 2023 | 2.28 Bn |
| Jun 30, 2023 | 4.51 Bn |
| Mar 31, 2023 | 2.77 Bn |
| Dec 31, 2022 | 5.50 Bn |
| Sep 30, 2022 | 4.60 Bn |
| Jun 30, 2022 | 3.30 Bn |
| Mar 31, 2022 | 4.72 Bn |
| Dec 31, 2021 | 5.07 Bn |
| Sep 30, 2021 | 4.31 Bn |